BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
← catalyst calendarNCT04982393 · readout in 744 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
207actual
Sites
30
Countries
Belgium, Canada, France +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-13 | actual | When the study began enrolling |
| Primary completion | 2028-09-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-09-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Hyperoxaluria Type 1
Primary outcome
what the primary-completion date above is the date OFIncidence of Adverse Events in Lumasiran Treated Patients
measured Up to 7 years
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed